Preview

Медицинский Совет

Расширенный поиск

Побочные эффекты адъювантной гормонотерапии

https://doi.org/10.21518/2079-701X-2018-10-64-69

Полный текст:

Аннотация

Гормонотерапия является высокоэффективным и в целом хорошо переносимым методом лечения гормонозависимого рака молочной железы. Тем не менее существует ряд побочных эффектов, которые могут снижать качество жизни пациенток и являться причиной преждевременной отмены препаратов. В статье обсуждаются основные нежелательные явления гормонотерапии: менопаузальные симптомы, гинекологические эффекты тамоксифена, сердечно-сосудистые, скелетно-мышечные осложнения. Некоторые из них могут быть предотвращены или скорректированы. Для сохранения удовлетворительного качества жизни пациенток следует больше внимания уделять побочным эффектам, действительно его снижающим, и не проявлять избыточной активности по поводу клинически незначащих проявлений.

Об авторах

E. И. Коваленко
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России
Россия

Кандидат медицинских наук



И. Б. Кононенко
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России
Россия

Кандидат медицинских наук



А. В. Снеговой
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России
Россия
Доктор медицинских наук


О. П. Гребенникова
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России
Россия

Кандидат медицинских наук



Л. В. Манзюк
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России
Россия
Доктор медицинских наук, профессор


Список литературы

1. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet, 2005, 365: 1687–1717.

2. Davies C et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level metaanalysis of randomized trials. Lancet, 2011, 27: 771-778.

3. Font R. et al. Prescription refill, patient selfreport and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia. Br J Cancer, 2012, 107: 1249-1256.

4. Barron T et al. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer, 2007, 109: 832-9.

5. Osborne O et al. Estrogen receptors in breast cancer therapy. Sci Med, 1996, 3: 32-41.

6. Dutertre M et al. Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther, 2000, 295: 431437.

7. Perez EA. Safety profiles of tamoxifen and aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol, 2007, 18(8): 26-35.

8. Mar Fan HG et al. Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: a prospective controlled study. Ann Oncol, 2010, 21: 983-7.

9. Morrow P et al. Hot flushes: a review of pathophysiology and treatment modalities. Oncologist, 2011, 16: 1658-64.

10. Howell A et al. Results of the ATAC (Arimidex, Tamoxifen alone or in Combination) trial after completion of 5 years adjuvant treatment for breast cancer. Lancet, 2005, 365: 60-62.

11. Thurlimann B et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Eng J Med, 2005, 353: 2747-2756.

12. Moraska AR et al. Management of hot flushes in breast cancer patients. EJCMO, 2012, 4: 1.

13. Holmberg L et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst, 2008, 100: 475-82.

14. L’Esperance S et al. Pharmacological and nonhormonal treatment of hot flushes in breast cancer survivors. Support Care Cancer, 2013, 21: 1461-74.

15. Wisniewska I et al. The pharmacological and hormonal treatment of hot flushes in breast cancer survivors. Breast Cancer, 2016, 23: 178-182.

16. Kligman L et al. Management of hot flushes in women with breast cancer. Curr Oncol, 2010, 17: 81-6.

17. Tevaarwerk A et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone-receptor positive breast cancer: a trial of Eastern Cooperative Oncology Group. J Clin Oncol, 2014 Dec 10, 32(35): 3948-58.

18. Lee KC, Ray GT, Hunkeler EM, et al. Tamoxifen treatment and new-onset depression in breast cancer patients. Psychosomatics, 2007, 48(3): 205–210.

19. Thompson DS, Spanier CA, Vogel VG. The relationship between tamoxifen, estrogen, and depressive symptoms. Breast J, 1999, 5(6): 375– 382.

20. Baumgart J, Nilsson K, Evers AS, et al. Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause, 2013, 20: 162-8.

21. Bernhard J et al. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomized trials. Lancer Oncol, 2015 Jul, 16(7): 848-58.

22. Schover LR. Counseling cancer patients about changes in sexual function. Oncology (Williston Park), 1999, 13: 1585-91, discussion 1591-2, 1595-6.

23. Taylor CE, Meisel JL. Management of Breast Cancer Therapy-Related Sexual Dysfunction. Oncology (Williston Park), 2017 Oct 15, 31(10): 726-9.

24. American College of Obstetricians and Gynecologists’ Committee on Gynecologic Practice, Farrell R. ACOG Committee Opinion No. 659: The Use of Vaginal Estrogen in Women With a History of Estrogen-Dependent Breast Cancer. Obstet Gynecol, 2016, 127: 93-96.

25. Nyrop KA et al. Weight gain during adjuvant endocrine treatment for early-stage breast cancer: what is the evidence? Breast Cancer Rea Treat, 2016 Jul, 158(2): 203-17.

26. Saquib N et al. Weight gain and recovery of pre-cancer weight after breast cancer treatments: evidence from the women’s healthy eating and living (WHEL) study. Breast Cancer Rea Treat, 2007 Oct, 105(2): 177-86.

27. Sestak I et al. Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. Breast Cancer Rea Treat, 2012 Jul, 134(2): 727-34.

28. NCCN Guidelines version 3.2017.

29. Polin S et al. The effect of tamoxifen on the genital tract. Cancer Imaging, 2008, 8: 135-145.

30. Coombes R et al. Intergroup exemestane study. A randomized exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Eng J Med, 2004, 350: 1081-1092.

31. Schlesinger C et al. Endometrial polyps: a comparison study of patients receiving tamoxifen with two control groups. Int J Gynecol Pathol, 1998, 17: 302–11.

32. Cheng WF et al. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol, 1997, 66: 233–7.

33. Cohen I et al. Adenomyosis in postmenopausal breast cancer patients treated with tamoxifen: a new entity? Gynecol Oncol, 1995, 58: 86–91.

34. Davies C et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptorpositive breast cancer: ATLAS, a randomised trial. Lancet, 2013 Mar 9, 381(9869): 805-16.

35. Early Breast Cancer Trialists’ Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized trials. Lancet, 2011 Aug 27, 378(9793): 771-84.

36. Liedman R et al. Disaccordance between estimation of endometrial thickness as measured by transvaginal ultrasound compared with hysteroscopy and directed biopsy in breast cancer patients treats with tamoxifen. Anticancer Res, 2006, 20(6C): 4889-92.

37. Gerber B et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective longterm study using transvaginal ultrasound. J Clin Oncol, 2000, 15, 18(20): 3464-70.

38. Mourits MJ et al. Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen. Gynecol Oncol, 1999, 73: 21–6.

39. American college of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG committee opinion. No 336: Tamoxifen and uterine cancer. Obstet Gynecol, 2006 Jun, 107(6): 1475-8.

40. Jakes R et al. Switching of postmenopausal women with endocrine responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG and ARNO trial. Lancet, 2005, 366: 455-462.

41. IBIS Investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet, 2002, 360: 817–824.

42. Deitcher S. The Risk of Venous Thromboembolic Disease Associated with Adjuvant Hormone Therapy for Breast Carcinoma. Cancer, 2004 August 1, 101(3): 439-449.

43. Braithwaite RS, Chlebowski RT, Lau J et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med, 2003, 18: 937–947.

44. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst, 2005, 97: 1262–1271.

45. Hadji P et al. Compliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of artralgia and compliance within the first year of adjuvant anastrozole therapy. Ann Oncol, 2014, 25: 372-377.

46. Henry S et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol, 2012, 30: 936-942.

47. Geisler J et al. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 20year treatment with exemestane: a randomized, placebo-controlled study. Eur J Cancer, 2006, 42: 2968-2975.

48. Nogues X et al. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer. Maturitas, 2010, 66: 291-297.

49. Khan Q et al. Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms and fatigue in women with breast cancer starting adjuvant letrosole. J Clin Oncol, 2013, 30(Suppl. Abstr 9000).

50. Servitja S et al. Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance. Ther Adv Med Oncol, 2015, 7(5): 291-296.

51. Sanders K et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA, 2010, 303: 1815-1822.

52. Vieth R et al. The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr, 2007, 85: 649-650.

53. Body JJ et al. Management of cancer treatmentinduced bone loss in early breast and prostate cancer a consensus paper of the Belgian Bone Club. Osteoporosis Int, 2007, 18: 1439–1450.

54. Coleman R et al. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol, 2014, 25(Suppl3): 124-137.

55. Hadji P, Aapro MS, Body JJ et al. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS and SIOGJ Bone. Oncol, 2017 Jun, 7: 1-12.

56. Gregory W et al. Adjuvant zoledronic acid (ZOL) in postmenopausal women with breast cancer and those rendered postmenopausal: results of a meta-analysis. J Clin Oncol, 2012, 30(Suppl 15): abstr 513.


Просмотров: 137


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)